Third Rock Ventures is a leading healthcare venture capital firm founded in 2007, with offices in Boston and San Francisco. The firm specializes in discovering, launching, and building innovative life science companies that aim to transform patient care. Since its inception, Third Rock has raised over $3.8 billion and invested in more than 60 companies, including Sage Therapeutics, Editas Medicine, Constellation Pharmaceuticals, and Flare Therapeutics.

Their portfolio spans various sectors, such as biotechnology, diagnostics, medical devices, digital health, and healthcare services. Third Rock's investment approach is characterized by a hands-on strategy, actively collaborating with founders to integrate deep scientific and medical expertise with operational and business acumen. This methodology has led to the development of 18 market-approved products across multiple therapeutic areas, including cancer, cardiovascular disease, depression, sickle cell disease, and rare genetic disorders.

The firm's mission is to be the preferred partner for entrepreneurs, investors, employees, and the industry, focusing on building companies that discover and develop products making a significant difference for patients.